Discover therapies designed for highly complex tumors.

Explore a portfolio developed for physicians seeking new alternatives for treatment-resistant tumors, immune evasion, and the need for therapeutic options with greater clinical differentiation.

 
 

Our therapies are designed for physicians seeking alternatives capable of improving the recognition of tumor cells and strengthening immune activity against complex neoplasms.

The portfolio brings together autologous, heterologous, and dual checkpoint blockade solutions to expand therapeutic possibilities for patients with immunosuppression, tumor refractoriness, or advanced disease.

Incorporate a portfolio with therapeutic differentiation, immunological foundation, and technical support that strengthens your clinical offering for highly demanding oncology patients.

Therapeutic solutions with real clinical value.

Gencell Oncology offers natural killer cell therapies for physicians who require new options for resistant tumors, complex disease, and scenarios where conventional alternatives are limited.

Depiction of Natural Killer cells attacking tumor cells

Request specialized information and discover which product can strengthen your therapeutic strategy.

Product portfolio

Syringe of autologous Natural Killer Cell NK5 by Gencell Oncology

Autologous Natural Killer Cells

Therapy with pretreated autologous NK cells aimed at enhancing the immune response and improving tumor visibility in complex neoplasms.

Syringe of heterologous Natural Killer Cell NK5 by Gencell Oncology

Heterologous Natural Killer Cells

Alternative using NK cells from a qualified donor for patients who are immunosuppressed or undergoing treatments that compromise immune activity.

Syringe of heterologous Double Blockade Natural Killer by Gencell Oncology

NK Heterologous Blockade

High-potency heterologous therapy designed to strengthen the immune response in complex patients requiring greater antitumor activation.

Syringe of autologous Double Blockade Natural Killer by Gencell Oncology

NK Autologous Blockade

Combination of autologous NK cells with nivolumab and ipilimumab to overcome immune evasion and expand options in refractory or advanced tumors.

Looking for a therapy aligned with your patient’s clinical profile? Request specialized guidance.

¿Te ayudamos?

Déjanos tus datos y un asesor te contacta. Sin compromiso.

Al enviar aceptas que Gencell te contacte. Tus datos no se comparten con terceros.

¡Gracias!

Hemos recibido tus datos. Un asesor te contacta en breve.